CAR T-cell Therapy

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.

Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Two novel CAR T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses ways of extending the reach of CAR T-cell therapy in real-world practice.

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Christine N. Duncan, MD, senior physician, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the use of CAR T-cell therapy in the treatment of pediatric patients with acute lymphocytic leukemia (ALL).

Prasad S. Adusumilli, MD, sheds light on the preliminary phase I data from a trial of CAR T-cell therapy in malignant pleural disease from mesothelioma.

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses real-world data with CAR T-cell therapy from the 2018 ASH Annual Meeting.

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discussed the results of a phase I study exploring mesothelin-targeted CAR T-cell therapy in patients with advanced solid tumors during the 2019 AACR Annual Meeting.

CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.

The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

Sequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplant.

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

Stephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses preliminary data on bb21217 in multiple myeloma.

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.